NCT04674241: Dexmedetomidine Alleviates Postoperative Delirium After Brain Tumor Resections

NCT04674241
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Not Applicable
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must be undergoing selective frontotemporal tumor resection
Exclusions: 
https://ClinicalTrials.gov/show/NCT04674241

Comments are closed.

Up ↑